Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing operations of $8.3 million and Free Cash Flow¹ of $6.6 million 14th consecutive quarter of positive Cash Flow from continuing operations and 10th consecutive quarter of positive Free Cash Flow¹ FY...
Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing operations of $8.3 million and Free Cash Flow¹ of $6.6 million 14th consecutive quarter of positive Cash Flow from continuing operations and 10th consecutive quarter of positive Free Cash Flow¹ FY 2025 Net Cash provided from continuing operations of $33.9 million and Free Cash Flow¹ of $25.3 million TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the fourth quarter and full year ended December 31, 2025. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial measures are reported as results from continuing operations unless otherwise noted, due to the Company’s previously stated intention to sell all of its Michigan assets, which are reported as discontinued operations effective as of the second quarter ended June 30, 2025. All historical periods have been restated accordingly. Fourth Quarter 2025 Financial Highlights Net Revenue was $66.1 million, compared to $65.1 million in Q3 2025. was $66.1 million, compared to $65.1 million in Q3 2025. Gross Profit Margin was flat at 52.1%, compared to Q3 2025. was flat at 52.1%, compared to Q3 2025. GAAP Net Loss from continuing operations was $0.5 million, compared to net loss of $9.9 million in Q3 2025. was $0.5 million, compared to net loss of $9.9 million in Q3 2025. EBITDA from continuing operations¹ was $11.5 million, compared to $14.3 million in Q3 2025. was $11.5 million, compared to $14.3 million in Q3 2025. Adjusted EBITDA from continuing operations¹ was $16.7 million, compared to $17.0 million in Q3 2025. was $16.7 million, compared to $17.0 millio...
Aperture Investors initiated a new position in Impinj (PI 7.82%), acquiring 117,118 shares valued at $20.38 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened According to a SEC filing dated February 17, 2026, Aperture Investors established a new position in Impinj, acquiring 117,118 shares during the fourth quarter of 2025. The fund reported a quarter-end h...
Aperture Investors initiated a new position in Impinj (PI 7.82%), acquiring 117,118 shares valued at $20.38 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened According to a SEC filing dated February 17, 2026, Aperture Investors established a new position in Impinj, acquiring 117,118 shares during the fourth quarter of 2025. The fund reported a quarter-end holding valued at $20.38 million. What else to know This was a new position for Aperture Investors, LLC and represents 2.33% of its 13F reportable AUM as of December 31, 2025. Top holdings after the filing: NYSE:CAVA: $30.05 million (4.2% of AUM) NYSE:BROS: $26.60 million (3.7% of AUM) NYSE:ORA: $25.59 million (3.6% of AUM) NASDAQ:VXUS: $25.58 million (3.6% of AUM) NASDAQ:POWL: $24.45 million (3.4% of AUM) As of Thursday, Impinj shares were priced at $91.62, up just 0.4% over the past year and well underperforming the S&P 500’s roughly 20% gain in the same period. Company overview Metric Value Revenue (TTM) $361.07 million Net Income (TTM) ($10.85 million) Price (as of Thursday) $91.62 One-Year Price Change 0.4% Company snapshot Impinj offers a cloud connectivity platform, including endpoint ICs, reader ICs, readers, gateways, and related software for item-level wireless identification and tracking. The firm generates revenue by selling hardware and software solutions that enable partners and end-users to connect, identify, and manage physical items across various industries. It serves retail, supply chain and logistics, aviation, automotive, healthcare, industrial, and other sectors through distributors, system integrators, value-added resellers, and software partners. Impinj, Inc. is a technology company specializing in wireless item connectivity and identification, enabling businesses to gain real-time visibility into their assets and inventory. The company leverages a scalable platform that integrates hardware and software for wireless item connectivity and identificatio...
El Pollo Loco press release ( LOCO ): Q4 Non-GAAP EPS of $0.25 beats by $0.05 . Revenue of $123.5M (+8.1% Y/Y) beats by $0.92M . The Company is providing the following expectations for 2026: System-wide comparable restaurant sales growth of 1.0% to 3.0% The opening of three to four company-operated restaurants and 15 to 16 franchised restaurants. Capital spending between $37.0 million and $40.0 mi...
El Pollo Loco press release ( LOCO ): Q4 Non-GAAP EPS of $0.25 beats by $0.05 . Revenue of $123.5M (+8.1% Y/Y) beats by $0.92M . The Company is providing the following expectations for 2026: System-wide comparable restaurant sales growth of 1.0% to 3.0% The opening of three to four company-operated restaurants and 15 to 16 franchised restaurants. Capital spending between $37.0 million and $40.0 million. G&A expense between $52.0 million and $54.0 million, excluding one-time costs. Adjusted EBITDA 1 between $66.0 million and $68.0 million Estimated effective income tax rate of approximately 29.0% before discrete items. More on El Pollo Loco El Pollo Loco Holdings Is On The Value Menu For A Reason El Pollo Loco Q4 2025 Earnings Preview El Pollo Loco makes menu innovation a big priority for 2026 Seeking Alpha’s Quant Rating on El Pollo Loco Historical earnings data for El Pollo Loco
The iShares Morningstar Small-Cap Growth ETF (ISCG 2.43%) features a lower cost and broader portfolio, while the iShares S&P Small-Cap 600 Growth ETF (IJT 2.28%) offers a higher yield, milder drawdowns, and greater assets under management. Both ISCG and IJT aim to provide exposure to U.S. small-cap growth stocks, but they take different approaches in portfolio construction, costs, and risk charact...
The iShares Morningstar Small-Cap Growth ETF (ISCG 2.43%) features a lower cost and broader portfolio, while the iShares S&P Small-Cap 600 Growth ETF (IJT 2.28%) offers a higher yield, milder drawdowns, and greater assets under management. Both ISCG and IJT aim to provide exposure to U.S. small-cap growth stocks, but they take different approaches in portfolio construction, costs, and risk characteristics. This comparison examines their fees, performance, risk, and holdings to help investors determine which may better fit their objectives. Snapshot (cost & size) Metric ISCG IJT Issuer IShares IShares Expense ratio 0.06% 0.18% 1-yr return (as of 2026-03-11) 24.7% 18.3% Dividend yield 0.6% 0.8% Beta 1.3 1.2 AUM $923.8 million $6.8 billion Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. ISCG is more affordable with a 0.06% expense ratio, while IJT charges 0.18% but compensates with a higher 0.8% dividend yield versus ISCG’s 0.6%—a potential draw for income-focused investors. Expand NYSEMKT : ISCG iShares Trust - iShares Morningstar Small-Cap Growth ETF Today's Change ( -2.43 %) $ -1.37 Current Price $ 55.07 Key Data Points Day's Range $ 54.97 - $ 55.75 52wk Range $ 38.73 - $ 60.19 Volume 89K Performance & risk comparison Metric ISCG IJT Max drawdown (5 y) -41.5% -29.2% Growth of $1,000 over 5 years $1,072 $1,091 Expand NASDAQ : IJT iShares Trust - iShares S&P Small-Cap 600 Growth ETF Today's Change ( -2.28 %) $ -3.33 Current Price $ 142.78 Key Data Points Day's Range $ 142.76 - $ 144.29 52wk Range $ 107.38 - $ 154.71 Volume 92K What's inside IJT tracks a portfolio of 355 U.S. small-cap growth companies, with sector exposures led by industrials (19%), technology (19%), and healthcare (14%). Its largest holdings—Interdigital (IDCC 1.62%), Moog Inc Class A (MOG-A), and CareTrust REIT (CTRE +0.78%)—each represent just over 1% of assets, and the fu...
Rubrik press release ( RBRK ): Q4 Non-GAAP EPS of $0.04 beats by $0.15 . Revenue of $377.68M (+46.3% Y/Y) beats by $35.31M . First Quarter and Fiscal Year 2027 Outlook Rubrik is providing the following guidance for the first quarter of fiscal year 2027 and the full fiscal year 2027: First Quarter Fiscal 2027 Outlook: Revenue of $365 million to $367 million vs consensus of $350.56M. Non-GAAP subscr...
Rubrik press release ( RBRK ): Q4 Non-GAAP EPS of $0.04 beats by $0.15 . Revenue of $377.68M (+46.3% Y/Y) beats by $35.31M . First Quarter and Fiscal Year 2027 Outlook Rubrik is providing the following guidance for the first quarter of fiscal year 2027 and the full fiscal year 2027: First Quarter Fiscal 2027 Outlook: Revenue of $365 million to $367 million vs consensus of $350.56M. Non-GAAP subscription ARR contribution margin of 10%-11%. Non-GAAP net loss per share of $(0.04) to $(0.02) vs consensus of -$0.07. Weighted-average shares outstanding of approximately 204 million. Full Year 2027 Outlook: Subscription ARR between $1,829 million and $1,839 million. Revenue of $1,597 million to $1,607 million vs consensus of $1.58B. Non-GAAP subscription ARR contribution margin of approximately 13%. Non-GAAP net income per share of $0.07 to $0.27 vs consensus of $0.07. Weighted-average shares outstanding of approximately 232 million. Free cash flow of $265 million to $275 million. Shares +6.53% AH.
PagerDuty press release ( PD ): Q4 Non-GAAP EPS of $0.29 beats by $0.04 . Revenue of $124.8M (+3.1% Y/Y) beats by $1.84M . Annual recurring revenue ("ARR") as of January 31, 2026 grew 1% year over year to $499 million. Customers with ARR over $100 thousand grew 1% to 861 as of January 31, 2026, compared to 849 in the prior year. Dollar-based net retention rate was 98% as of January 31, 2026, compa...
PagerDuty press release ( PD ): Q4 Non-GAAP EPS of $0.29 beats by $0.04 . Revenue of $124.8M (+3.1% Y/Y) beats by $1.84M . Annual recurring revenue ("ARR") as of January 31, 2026 grew 1% year over year to $499 million. Customers with ARR over $100 thousand grew 1% to 861 as of January 31, 2026, compared to 849 in the prior year. Dollar-based net retention rate was 98% as of January 31, 2026, compared to 106% in the prior year. Free and paid customers totaled more than 35,000 as of January 31, 2026 representing approximately 14% growth year over year. Total paid customers were 15,351 as of January 31, 2026, compared to 15,114 in the prior year. Remaining performance obligations were $449 million as of January 31, 2026. Of this amount, the Company expects to recognize revenue of approximately $314 million, or 70%, over the next 12 months, $106 million, or 24%, over months 13 to 24, and the remainder thereafter. For the first quarter of fiscal 2027, PagerDuty currently expects: Total revenue of $118.0 million - $120.0 million. Non-GAAP net income per diluted share attributable to PagerDuty, Inc. common stockholders of $0.23 - $0.25 assuming approximately 83 million diluted shares and a non-GAAP tax rate of 20%. For the full fiscal year 2027, PagerDuty currently expects: Total revenue of $488.5 million - $496.5 million. Non-GAAP net income per diluted share attributable to PagerDuty, Inc. common stockholders of $1.23 - $1.28 assuming approximately 81 million diluted shares and a non-GAAP tax rate of 20%. Shares -9% . More on PagerDuty PagerDuty: Major Supporter Now Selling PagerDuty: Challenging Business, But Possible M&A Target Optionality PagerDuty, Inc. (PD) Presents at 28th Annual Needham Growth Conference - Slideshow Extended enterprise software selloff hits seat-based business models hardest: Truist PagerDuty dips after RBC Capital cuts rating
May NY world sugar #11 (SBK26) on Thursday closed up +0.13 (+0.91%), and May London ICE white sugar #5 (SWK26) closed up +0.70 (+0.17%). Sugar prices settled higher on Thursday but remained below Monday's 2-month highs. Thursday's +7% surge in crude oil prices (CLK26) was supportive for sugar. Higher crude oil prices support ethanol prices, encouraging the world's sugar mills to divert cane crushi...
May NY world sugar #11 (SBK26) on Thursday closed up +0.13 (+0.91%), and May London ICE white sugar #5 (SWK26) closed up +0.70 (+0.17%). Sugar prices settled higher on Thursday but remained below Monday's 2-month highs. Thursday's +7% surge in crude oil prices (CLK26) was supportive for sugar. Higher crude oil prices support ethanol prices, encouraging the world's sugar mills to divert cane crushing toward ethanol production rather than sugar, thereby reducing sugar supplies. Don’t Miss a Day: On February 12, sugar prices plunged to 5.25-year nearest-futures lows on concern that a global sugar surplus will persist. On February 11, analysts from sugar trader Czarnikow said they expect a global sugar surplus of 3.4 MMT in the 2026/27 crop year, following an 8.3 MMT surplus in 2025/26. Also, Green Pool Commodity Specialists said on January 29 that they expect a 2.74 MMT global sugar surplus for 2025/26 and a 156,000 MT surplus for 2026/27. Meanwhile, StoneX said February 13 that it expects a global sugar surplus of 2.9 MMT in 2025/26. The International Sugar Organization (ISO) on February 27 forecasted a +1.22 MMT (million metric ton) sugar surplus in 2025-26, following a -3.46 MMT deficit in 2024-25. ISO said the surplus is being driven by increased sugar production in India, Thailand, and Pakistan. ISO is forecasting a +3.0% y/y rise in global sugar production to 181.3 million MMT in 2025-26. Signs of lower sugar output in Brazil are supportive of sugar prices, after Unica on February 18 reported that sugar production in Brazil's Center-South in the second half of January fell by -36% y/y to only 5,000 MT. However, cumulative 2025-26 Center-South sugar output through January rose +0.9% y/y to 40.24 MMT. The Indian Sugar and Bio-energy Manufacturers Association (ISMA) reported on March 6 that India's 2025-26 sugar output from Oct 1-Feb 28 was up +12% y/y to 24.75 MMT. Last Wednesday, the ISMA projected India's 2025/26 sugar production at 29.3 MMT, up 12% y/y, below an...
May ICE NY cocoa (CCK26) on Thursday closed down -114 (-3.32%), and May ICE London cocoa #7 (CAK26) closed down -79 (-3.18%). Cocoa prices settled sharply lower on Thursday amid optimism that rain in West Africa will boost cocoa crop yields. Weather forecaster Vaisala said it expects rainfall to continue into next week for most of West Africa, which should support cocoa crop flowering. Don’t Miss ...
May ICE NY cocoa (CCK26) on Thursday closed down -114 (-3.32%), and May ICE London cocoa #7 (CAK26) closed down -79 (-3.18%). Cocoa prices settled sharply lower on Thursday amid optimism that rain in West Africa will boost cocoa crop yields. Weather forecaster Vaisala said it expects rainfall to continue into next week for most of West Africa, which should support cocoa crop flowering. Don’t Miss a Day: Ample supplies are also weighing on cocoa prices as ICE cocoa inventories rose to a 7-month high of 2,251,404 bags on Thursday. NY cocoa rallied to a 3-week high on Wednesday after a Reuters report on Tuesday said that local grinders bought more than 400,000 metric tons of Ivory Coast cocoa export contracts in the 10 days since purchases resumed for the mid-year crop. That suggested that new demand is emerging in the wake of recent cocoa price cuts. Last month, Ghana cut the official price it pays its cocoa farmers by nearly 30% for supplies for the 2025/26 growing season, and the Ivory Coast last Wednesday said it would cut cocoa farmer pay by 57% that would kick in for the mid-crop harvest that started in March. The Ivory Coast and Ghana produce more than half of the world's cocoa. Cocoa prices have also seen some support since last week as the closure of the Strait of Hormuz has boosted global shipping rates, insurance costs, and fuel prices, thereby raising cocoa importers' costs. In addition, slowing cocoa deliveries to ports in the Ivory Coast is supportive of prices. Monday's cumulative data from the Ivory Coast showed that Ivory Coast farmers shipped 1.35 MMT of cocoa to ports in the current marketing year (October 1, 2025, through March 1, 2026), down -3.6% from 1.40 MMT in the same period a year ago. Demand concerns have hammered cocoa prices as consumers continue to balk at the high price of chocolate. On January 28, Barry Callebaut AG, the world's largest bulk chocolate maker, reported a -22% decline in sales volume in its cocoa division for the quarter e...
May arabica coffee (KCK26) on Thursday closed up by +4.50 (+1.57%), and May ICE robusta coffee (RMK26) closed up by +72 (+2.03%). Coffee prices finished sharply higher on Thursday due to the Iran war, which has closed the Strait of Hormuz and disrupted global shipping. Iran’s Supreme Leader Ayatollah Mojtaba Khamenei said today that Iran’s leverage of closing the Strait of Hormuz should be used, a...
May arabica coffee (KCK26) on Thursday closed up by +4.50 (+1.57%), and May ICE robusta coffee (RMK26) closed up by +72 (+2.03%). Coffee prices finished sharply higher on Thursday due to the Iran war, which has closed the Strait of Hormuz and disrupted global shipping. Iran’s Supreme Leader Ayatollah Mojtaba Khamenei said today that Iran’s leverage of closing the Strait of Hormuz should be used, and UK Defense Secretary Healey said it is increasingly evident that Iran is laying mines in the Strait of Hormuz. The closure of the waterway has increased global shipping rates, insurance, and fuel costs, and raises costs for coffee importers and roasters. Don’t Miss a Day: Gains in coffee prices were limited on Thursday amid favorable weather in Brazil, as showers are forecast in key coffee-growing areas. Also, StoneX on Thursday raised its Brazil 2026/27 coffee production estimate to a record 75.3 million bags, up from its November estimate of 70.7 million bags. In supportive news, Somar Meteorologia reported on Monday that Brazil’s largest arabica coffee-growing area, Minas Gerais, received 14.9 mm of rain last week, or 35% of the historical average. Coffee prices also saw support from last Tuesday’s news that Brazil’s green coffee exports in February fell by -27% y/y, according to Cecafe. Meanwhile, Brazil’s Trade Ministry reported last Thursday that Brazil’s Feb coffee exports fell -17.4% y/y to 142,000 MT. Rising ICE inventories also pressure coffee prices. ICE-monitored arabica inventories rose to a 5-month high of 564,626 bags on Tuesday but fell back slightly to 552,192 bags on Wednesday. ICE robusta coffee inventories posted a 3.5-month high of 4,721 lots on March 3 but have since fallen back to 4,550 lots as of today. Coffee prices in February sold off sharply, with arabica falling to a 15-month low on February 24 and robusta tumbling to a 6.75-month low on February 23 as signs of a bumper Brazilian coffee crop supported the global supply outlook. On February 5,...
A general view of the WNBA logo on the court before a WNBA game between the Atlanta Dream and the Connecticut Sun on Sept. 1, 2025, at Mohegan Sun Arena in Uncasville, CT. Erica Denhoff | Icon Sportswire | Getty Images The Women's National Basketball Association and its Players Association are inching closer to a collective bargaining agreement, now two days past their self-imposed deadline. The p...
A general view of the WNBA logo on the court before a WNBA game between the Atlanta Dream and the Connecticut Sun on Sept. 1, 2025, at Mohegan Sun Arena in Uncasville, CT. Erica Denhoff | Icon Sportswire | Getty Images The Women's National Basketball Association and its Players Association are inching closer to a collective bargaining agreement, now two days past their self-imposed deadline. The parties have been meeting around the clock at a midtown hotel in New York City, with negotiations stretching into the late morning hours to hammer out a deal, according to a person familiar with the process, who was not authorized to speak publicly. In the last 48 hours, there have been eight proposals exchanged between both sides addressing nearly every issue up for discussion, the person said. The negotiations come as women's sports have seen major financial growth from bigger media deals and strong demand. The WNBA previously said the new CBA would need to be in place by March 10 in order to start their season on time. Negotiations between continued Thursday. It's unclear what the delay will mean for the scheduled season start. WNBPA President Nneka Ogwumike told reporters late Wednesday that players are "feeling movement" in the talks. The Players Association said it has been and will continue to be fully engaged in the negotiations. "We want to play. We've heard that from the other side as well," Ogwumike told reporters. The latest league proposal included increases in nearly every category, according to a copy of the details obtained by CNBC. According to the proposal, the league is offering a salary cap four times higher than the current cap — at $6.2 million up from the existing cap of $1.5 million. That cap would grow annually with team and league revenue growth, per the proposal. Average salaries would also see a major increase, starting at $570,000 in year one and growing to $850,000 in year six. The current average player salary in the league is about $120,000, a...
Maro Itoje hassaid there are no cracks in the England squad despite his spat with Fin Smith during last week’s humiliating defeat by Italy and believes the confrontation demonstrates the harmony within the camp. Itoje was heard roaring at Smith “don’t argue with me, take the three,” in the 43rd minute of the defeat in Rome with the fly-half eager to kick to the corner and push for a try with Engla...
Maro Itoje hassaid there are no cracks in the England squad despite his spat with Fin Smith during last week’s humiliating defeat by Italy and believes the confrontation demonstrates the harmony within the camp. Itoje was heard roaring at Smith “don’t argue with me, take the three,” in the 43rd minute of the defeat in Rome with the fly-half eager to kick to the corner and push for a try with England 12-10 to the good. Ellis Genge, one of two vice-captains, also wanted to go for the try but Jamie George, the other, wanted a kick at goal. Itoje vehemently disagreed with Smith and overruled his fly-half, who duly kicked the penalty. England built an 18-10 lead thanks to another Smith penalty but then unravelled with Sam Underhill and Itoje shown yellow cards and Italy coming from behind to secure a famous 23-18 victory. As a result, to avoid their worst ever Six Nations campaign this weekend England must claim a first away win against France since 2016. Itoje is adamant that the incident with Smith does not demonstrate any splits within the side. “There’s no crack, there’s no crack between us,” said Itoje. “He’s a good guy and I get on with him very well and I think when you have good relationships with people you’re able to have those sorts of conversations and are able to move on from it pretty quickly. There was no residue from that. Naturally, I guess because of the loss, it was made into a bigger thing than it actually was. “I actually think it is a good thing that people in the team feel they can express a view and in sport, if anything, that’s the most kosher of fallouts that the world has ever seen. We have had far more blunt conversations between ourselves and other teammates. “There’s no real biggie. After that interaction, we even laughed about it a little bit on the pitch as well. Fin is my guy. As always when it comes to things, the way I try to do things is I like to hear what my key decision makers think of what is going on and that whoever plays 10 they...
A man was killed after ramming his vehicle into the front doors of a synagogue in suburban Detroit on Thursday afternoon. There was an exchange of gunfire with security staff. Police say the driver died in the car, but the cause of death has not been determined. Multiple law enforcement agencies, including the FBI, responded to the scene. Bloomberg's Myles Miller joins Bloomberg Businessweek Daily...
A man was killed after ramming his vehicle into the front doors of a synagogue in suburban Detroit on Thursday afternoon. There was an exchange of gunfire with security staff. Police say the driver died in the car, but the cause of death has not been determined. Multiple law enforcement agencies, including the FBI, responded to the scene. Bloomberg's Myles Miller joins Bloomberg Businessweek Daily with the latest. (Source: Bloomberg)
Ulta Beauty press release ( ULTA ): Q4 GAAP EPS of $8.01 misses by $0.02 . Revenue of $3.89B (+11.5% Y/Y) beats by $70M . Net sales increased 11.8% to $3.9 billion, primarily due to increased comparable sales, the acquisition of Space NK, and sales from new stores. Comparable sales increased 5.8% and 5.4% for the fourth quarter and fiscal year, respectively Provided fiscal 2026 guidance for net sa...
Ulta Beauty press release ( ULTA ): Q4 GAAP EPS of $8.01 misses by $0.02 . Revenue of $3.89B (+11.5% Y/Y) beats by $70M . Net sales increased 11.8% to $3.9 billion, primarily due to increased comparable sales, the acquisition of Space NK, and sales from new stores. Comparable sales increased 5.8% and 5.4% for the fourth quarter and fiscal year, respectively Provided fiscal 2026 guidance for net sales growth of 6.0% to 7.0% and diluted EPS growth of 9.4% to 11.4% Shares -2% . More on Ulta Beauty Ulta Beauty: Quarterly Preview And The Case For A Premium Ulta Beauty: Relief Rally Went Overboard Ulta Beauty: Strong Comp Sales As Retail Sector Looks To Rebound Ulta earnings preview: Traders bet market share and holiday demand will dominate the call Ulta Beauty has a Selena Gomez catalyst in play
Ja'Crispy/iStock via Getty Images Written by Nick Ackerman, co-produced by Stanford Chemist Bexil Investment Trust ( BXSY ) is a more unusual closed-end fund, trading OTC, and that's at least one reason that it trades at a substantial discount. The discount hasn't changed too much since our prior update, which sat at ~37.5%, and today it is around ~36.5%. However, since our last update, the fund h...
Ja'Crispy/iStock via Getty Images Written by Nick Ackerman, co-produced by Stanford Chemist Bexil Investment Trust ( BXSY ) is a more unusual closed-end fund, trading OTC, and that's at least one reason that it trades at a substantial discount. The discount hasn't changed too much since our prior update, which sat at ~37.5%, and today it is around ~36.5%. However, since our last update, the fund has also blasted higher in terms of total returns. This has far exceeded the results of the broader equity benchmark, the S&P 500 Index. This is primarily thanks to its differentiated portfolio. Relatively speaking, its technology sector sleeve is quite small, with the largest allocations to financial services, consumer cyclicals, and basic materials far dwarfing the tech allocation. While the fund doesn't always outperform a simple allocation to the SPDR S&P 500 Index ETF ( SPY ), it has been quite competitive for a number of years now. If one believes that relatively undervalued areas of the market can continue to outperform, then BXSY also continues to be a strong place to consider allocating. Even for speculative investors looking at that ~36%+ discount level, it could be an interesting bet to make these days. BXSY Basics 1-Year Z-score: 0.31 Discount/Premium: -36.54% Distribution Yield: 6.63% Expense Ratio: 1.39% Leverage: 0% Managed Assets: $306 million Structure: Perpetual BXSY's investment objective is "high current income" with a secondary "capital appreciation" goal. To achieve that, the fund will invest, "under normal circumstances, at least 50% of its total assets in income-generating equity securities." The fund targets "companies with strong operations showing superior returns on equity and assets with reasonable valuations. Generally, the Fund purchases and holds income-generating equity securities of profitable, growing, and conservatively valued companies across a broad array of industries." Since our last update, they have taken leverage down to 0%. Althoug...
Adobe press release ( ADBE ): Q1 Non-GAAP EPS of $6.06 beats by $0.19 . Revenue of $6.4B (+12.1% Y/Y) beats by $120M . The following table summarizes Adobe’s second quarter FY2026 targets: Total revenue $6.43 billion to $6.48 billion vs consensus of $6.43B Business Professionals & Consumers subscription revenue $1.80 billion to $1.82 billion Creative & Marketing Professionals subscription revenue ...
Adobe press release ( ADBE ): Q1 Non-GAAP EPS of $6.06 beats by $0.19 . Revenue of $6.4B (+12.1% Y/Y) beats by $120M . The following table summarizes Adobe’s second quarter FY2026 targets: Total revenue $6.43 billion to $6.48 billion vs consensus of $6.43B Business Professionals & Consumers subscription revenue $1.80 billion to $1.82 billion Creative & Marketing Professionals subscription revenue $4.41 billion to $4.44 billion Earnings per share 1 GAAP: $4.35 to $4.40 Non-GAAP: $5.80 to $5.85 vs consensus of $5.68 Click to enlarge Shares +0.35% AH.
The coefficient is safe. The coefficient is yours. You’re going home with the coefficient. But perhaps not, on this evidence, with the microwave, the washing machine or the Jet Ski. England’s soccer shame. Premier League in EURO MELTDOWN. Robot-ball crisis: how Arteta’s Arsenal destroyed all that is good and true, including the ploughman’s lunch and probably Woolworths. This kind of stuff has begu...
The coefficient is safe. The coefficient is yours. You’re going home with the coefficient. But perhaps not, on this evidence, with the microwave, the washing machine or the Jet Ski. England’s soccer shame. Premier League in EURO MELTDOWN. Robot-ball crisis: how Arteta’s Arsenal destroyed all that is good and true, including the ploughman’s lunch and probably Woolworths. This kind of stuff has begun to do the rounds after this week’s Champions League last-16 matches. For English football it is a striking executive summary. Six Premier League teams played the first legs of their last-16 ties on Tuesday and Wednesday. End result: four defeats and two draws. Three of those defeats were semi-thrashings by three goals. Newcastle played well against strong opponents. Nobody else did. Only Arsenal and Liverpool look more likely than not to get to the quarter-finals. Why has this happened? Is it actually a bad thing? How does it explain not only the complex, self-limiting dynamics of elite club football, but also the fact England are less likely to win the World Cup this summer than most people seem to assume? Maybe, who knows, it doesn’t explain any of these things [narrator’s voice: it does]. There is an obvious counterpoint. It’s still half-time. Take a breath. Mush an orange segment into your front teeth. Manchester City and Chelsea are capable of scoring three goals at home next week. Newcastle can get a draw at the Camp Nou. Tottenham … well, OK, Tottenham. But their opponents have flaws too, and football is increasingly swing-prone. Either way, the Premier League will still probably end up with two teams in the last eight. This seems an objectively reasonable outcome. The Champions League is contested by 55 Uefa members. The notion of six English teams in the quarter-finals should be deeply offputting to anyone who likes the idea of robust competition or a fun run of games to watch on TV. The sense of collective failure in train springs solely from finance. The Premie...
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient do...
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient dosing in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial of rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with disease progression on at least one prior line of therapy (PiNACLE-H2H). Lyell has dosed seven new patients with metastatic colorectal cancer (mCRC) with LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, since its November 2025 acquisition, without dose-limiting toxicity and including dose escalation to Dose Level 3.
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026 -- Approximately $59M in cash and cash equivalents at the end of Q4 2025 BOULDER, Colo., March 12, 2026 (GLOBE NE...
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026 -- Approximately $59M in cash and cash equivalents at the end of Q4 2025 BOULDER, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent business highlights. “We are pleased with the continued progress across our PI3Kα‑focused pipeline, including the steady execution of the PIKture‑01 trial of OKI-219. We look forward to sharing updated data from this trial later this month,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure. “We are also excited to announce our next‑generation pan‑mutant inhibitor development candidate for HR+ metastatic breast cancer this month and provide additional information on our program in vascular malformations later this year. Overall, we believe our progress to date underscores the power of our mutation‑selective approach to PI3Kα inhibition and reinforces the momentum we are building as we work to deliver scientifically differentiated therapies to patients.” OKI-219 Program Highlights OnKure’s lead product candidate, OKI-219, is a highly selective PI3kαH1047 mutant specific inhibitor. OKI-219 is being evaluated in the PIKture-01 phase 1a/1b clinical trial for the treatment of patients with HR+ and HER2+ metastatic breast cancer. Parts A and B – Enrollment in both the monotherapy and fulvestrant combination dose escalation arms of the PIKture-01 trial has been completed and closed. A total of 71 patients have been dosed across both arms: 38 in monotherapy and 33 in combination with fulvestrant. ...
CHANDLER, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use of force training simulators and firearms training simulators for the law enforcement and military markets, will hold a conference call on Thursday, March 26, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the...
CHANDLER, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use of force training simulators and firearms training simulators for the law enforcement and military markets, will hold a conference call on Thursday, March 26, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. Financial results will be issued in a press release prior to the call. VirTra management will host the presentation, followed by a question-and-answer period. Date: Thursday, March 26, 2026 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) U.S. dial-in: 1-877-407-9208 International dial-in: 1-201-493-6784 Conference ID: 13758841 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860. The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website. A replay of the call will be available after 7:30 p.m. Eastern time on the same day through April 9, 2026. Toll-free replay number: 1-844-512-2921 International replay number: 1-412-317-6671 Replay ID: 13758841 About VirTra, Inc. VirTra (Nasdaq: VTSI) is a global provider of judgmental use-of-force and firearms training simulators for law enforcement, military, educational, and commercial markets. Since 1993, VirTra has been dedicated to saving lives by providing highly effective, realistic training designed to prepare officers for the most difficult real-world situations. Investor Relations Contact: Alec Wilson and Greg Bradbury Gateway Group, Inc. VTSI@gateway-grp.com 949-574-3860
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical ...
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes. Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026 BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ended December 31, 2025, and provided recent corporate and clinical updates. “In 2025, we made meaningful progress advancing ELI-002 7P in KRAS-mutant pancreatic cancer,” said Robert Connelly, Chief Executive Officer of Elicio. “We remain focused on completing the Phase 2 AMPLIFY-7P trial and reaching the event-driven primary DFS analysis expected in 1H 2026. We are encouraged by the continued observation of fewer disease progressions and deaths to date than projected in the 2:1 randomized trial, as well as by the durability of T-cell responses and clinical observations reported to date, which reinforce our confidence in ELI-002 7P’s potential to favorably impact outcomes. With capital expected to carry us beyond the anticipated DFS readout, we believe we are well positioned to deliver this important milestone and continue advancing our Amphiphile (“AMP”) platform in KRAS-mutant PDAC. We remain highly interested in the potential to expand the development of ELI-002 7P to neoadjuvant and metastatic PDAC and other KRAS+ tumors, with the goal of creating meaningful long-term value for patients and shareholders.” Recent Highlights In 2025, Elicio continued advancement of the randomized Phase...
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clin...
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update. “We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Given strong site engagement and enthusiasm, EVERLAST-A completed enrollment in December 2025, enabling us to bring our initial data release into the second quarter of 2026. Meanwhile, we are excited to be starting our Phase 2 efforts with ORKA-002, which we believe could be a very impactful program in psoriatic disease and HS.” Fourth Quarter 2025 and Recent Business and Pipeline Updates ORKA-001: A novel half-life extended IL-23p19 monoclonal antibody Enrollment in EVERLAST-A was completed in December 2025. As a result, the Company now expects to report Week 16 data for all patients in the second quarter of 2026. In addition, the Company plans to provide longer-term data, including Week 28 for all patients and 52-week follow-up for a portion of the cohort in the second half of 2026. The first patients were dosed in EVERLAST-B in December 2025 and enrollment is ongoing. EVERLAST-B is evaluating multiple induction regimens of ORKA-001, with a primary endpoint of PASI 100 at Week 16. Data from EVERLAST-B is anticipated in 2027 and will be used to support initiation of a Phase 3 program. ORKA-002: A novel half-life...
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), a leading provider of lending enablement and risk analytics solutions for financial institutions, today reported financial results for its fourth quarter and full year ended December 31, 2025. “I am proud to conclude my first year as Chief Executive Officer, during which we ...
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), a leading provider of lending enablement and risk analytics solutions for financial institutions, today reported financial results for its fourth quarter and full year ended December 31, 2025. “I am proud to conclude my first year as Chief Executive Officer, during which we made meaningful progress across all key areas of the business,” said Jessica Buss, Chief Executive Officer of Open Lending. “In 2025, we delivered strong revenue and adjusted EBITDA in our core business while reducing volatility with a materially flat profit share change in estimate. Throughout the year, we remained focused on disciplined underwriting and disciplined pricing, ensuring we selected the right business at the right price with the appropriate risk profile. We believe this approach strengthens our foundation and positions us for sustainable, profitable growth in 2026. “In addition, with the launch of the ApexOne Auto platform, we expanded our capabilities to the full auto credit spectrum, moving Open Lending beyond a single-product company and enabling us to operate as a full-scope lending platform. We believe these initiatives position us to deliver durable performance across credit cycles and provide consistent growth for our shareholders and customers.” Three Months Ended December 31, 2025 Highlights The Company facilitated 19,308 certified loans during the fourth quarter of 2025, compared to 26,065 certified loans in the fourth quarter of 2024. Total revenue was $19.3 million during the fourth quarter of 2025, compared to $(56.9) million in the fourth quarter of 2024. The fourth quarter of 2025 was impacted by an insignificant change in estimated profit share revenues related to business in historic vintages as compared to a reduction of $81.3 million in the fourth quarter of 2024. Gross profit was $14.7 million during the fourth quarter of 2025, compared to ...
~ Company Delivers Another Record Quarter, Beating Average Consensus by 20% ~ ~ Marks 11 Consecutive Quarters of Strong Earnings Growth ~ ~ Fourth Quarter and Full Year 2025 Revenue Up Over 100% Year-Over-Year ~ ~ Full Year 2025 GAAP Net Income of $36.5 Million; Adjusted Net Income of $85.7 Million ~ ~ Initiates Full Year 2026 Outlook for Adjusted Net Income to Between $96 and $104 Million ~ ~ Out...
~ Company Delivers Another Record Quarter, Beating Average Consensus by 20% ~ ~ Marks 11 Consecutive Quarters of Strong Earnings Growth ~ ~ Fourth Quarter and Full Year 2025 Revenue Up Over 100% Year-Over-Year ~ ~ Full Year 2025 GAAP Net Income of $36.5 Million; Adjusted Net Income of $85.7 Million ~ ~ Initiates Full Year 2026 Outlook for Adjusted Net Income to Between $96 and $104 Million ~ ~ Outlines Long-Term Strategic Growth Targets ~ ORLANDO, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ("Abacus" or the "Company") (NYSE: ABX), a leader in the alternative asset management industry, today reported results for the fourth quarter and full year ended December 31, 2025. Jay Jackson, Chief Executive Officer of Abacus commented, "We closed the year by delivering another strong quarter, achieving eleven consecutive quarters beating consensus. Quarter after quarter, we hit our guidance, exceeded expectations, expanded margins, and grew our asset base to approximately $3.6 billion—all while executing disciplined capital allocation with ROE and ROIC above 20%. Real results consistently delivered, not aspirations. This track record should give shareholders confidence as we lay out our 5-year path to becoming a mid-cap company operating at approximately $450 million in Adjusted EBITDA at scale, with recurring revenue representing 70% of our total revenue mix." Fourth Quarter 2025 Highlights Total revenue for the fourth quarter grew 116% to $71.9 million, compared to $33.2 million in the prior-year period. The increase was driven by a $32.9 million increase in Life Solutions revenue, a $5.6 million increase in Asset Management revenue, and a $235 thousand increase in Technology Services revenue. Origination capital deployment continued to expand, increasing by 82% for the quarter to $230.7 million, compared to $126.5 million in the prior-year period. GAAP net income attributable to shareholders was $7.2 million, compared to GAAP net loss of $18.3 mi...
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunothe...
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. “BDC-4182 is the first of our next-generation Boltbody™ ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated,” said Willie Quinn, President and Chief Executive Officer. “The ISAC mechanism is radically different from ADCs and T cell engagers, and we believe that demonstrating anti-tumor activity with BDC-4182 will unlock an entirely new approach to treating cancer. We continue to enroll patients with gastric and gastroesophageal cancers in the Phase 1 dose-escalation trial and remain on track to report initial data in the third quarter of 2026.” Recent Highlights and Anticipated Milestones Initial clinical data from BDC-4182 Phase 1 study for patients with gastric and gastroesophageal cancer expected in the third quarter of 2026. BDC-4182 is a next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and other tumor types. In preclinical models, including cancer models with low claudin 18.2 expression, BDC-4182 demonstrated significant anti-tumor activity, induced immunological memory, and outperformed cytotoxic claudin 18.2 ADCs. Following a strong immune response that was observed at the initial dose levels, Bolt modified the clinical trial protocol to allow for step-up dosing, which has been successfully ...
— Continued Profitable Growth and Business Expansion — CHINO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter ...
— Continued Profitable Growth and Business Expansion — CHINO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Record fourth quarter net sales of $115.6 million, up 13.7 percent, from $101.6 million in the prior-year quarter. Gross profit of $39.3 million, versus $39.8 million in the prior-year quarter. Gross margin of 34.0 percent, reflecting an expected decrease from 39.2 percent in the prior-year quarter due to elevated tariffs. Net income of $7.2 million, up 22.8 percent, from $5.9 million in the prior-year quarter. Net income margin of 6.2 percent, from 5.8 percent in the prior-year quarter. Adjusted EBITDA of $12.5 million, versus $11.3 million in the prior-year quarter. Adjusted EBITDA margin of 10.8 percent, versus 11.1 percent in the prior-year quarter. Guidance Net sales for the 2026 first quarter expected to increase by 8 to 10 percent from the prior-year quarter. Gross margin for the 2026 first quarter expected to be between 34 and 36 percent. Adjusted EBITDA margin for the 2026 first quarter expected to be between 9 and 11 percent. Net sales for full-year 2026 expected to increase by low double-digits from the prior year. Gross margin and adjusted EBITDA margin for full year 2026 expected to continue to improve compared with the prior year, under current global tariff policy. “We finished 2025 with a strong fourth quarter, demonstrating the strength and resilience of our business model and our ability to continue to drive profitable growth against an uncertain macroeconomic backdrop. We again achieved double-digit volume growth and our pricing turned positive for the first time since the first quarter of 2023,” said Alan Yu, Chief Executive Officer. “Our...
IRVINE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the fourth quarter and fiscal year ended January 2, 2026. Highlights Reported revenue of $100 million, which includes $84 million of Shimmick Projects revenue...
IRVINE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the fourth quarter and fiscal year ended January 2, 2026. Highlights Reported revenue of $100 million, which includes $84 million of Shimmick Projects revenue, for Q4 2025, and revenue of $493 million, which includes $397 million of Shimmick Projects revenue, for FY2025 Shimmick Projects Q4 2025 revenue up 4% year over year Shimmick Projects FY2025 revenue up 12% year over year Reported Q4 2025 gross margin of $10 million, all of which was driven by Shimmick Projects Shimmick Projects Q4 2025 gross margin up 462% year over year Shimmick Projects FY2025 gross margin up 232% year over year Recognized a Q4 2025 net loss of $3 million, largely attributable to Non-Core Projects Reported Q4 2025 Adjusted EBITDA of $4 million, our second consecutive quarter with positive EBITDA Reported liquidity of $44 million as of January 2, 2026 Backlog is approximately $793 million as of January 2, 2026 Q4 2025 Book-to-burn ratio of 1.4x, a 5% increase to backlog compared to Q3 2025 $139 million in new work was booked in Q4 2025, with Shimmick Projects representing over 89% of total backlog $128 million in new awards added to backlog as of the close of February 2026 $234 million in additional new awards were pending as of February 2026 in water and electrical target markets in California, Texas and Washington and are expected to contribute to 2026 backlog “Our strategy has been and continues to be growing our backlog with work that we believe will deliver consistent margins while improving operational performance”, said Ural Yal, Chief Executive Officer of Shimmick. “As expected, we delivered another quarter of book-to-burn ratio exceeding 1.0x and also expect new awards to continue into the new year, with new work wins that are geographically wit...